A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy
This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy. The objectives of the trial are to compare the efficacy and safety of afatinib versus methotrexate
Inclusion criteria:
Exclusion criteria:
Ciudad Autonoma de Bs As, Argentina
Haidari, Greece
Confreria (CN), Italy
Aichi, Nagoya, Japan
Chiba, Kashiwa, Japan
Hyogo, Akashi, Japan
Hyogo, Kobe, Japan
Kanagawa, Isehara, Japan
Miyagi, Natori, Japan
Osaka, Osaka, Japan
Tochigi, Shimotsuke, Japan
Tokyo, Koto-ku, Japan
Tokyo, Minato-ku, Japan
Kurski, Russia
Kraaifontein, Cape Town, South Africa
Parktown, Johannesburg, South Africa